UK-based Poolbeg Pharma (AIM: POLB) has announced that research conducted on its behalf confirms a market opportunity of at least $10 billon for POLB 001 in cancer immunotherapy-induced cytokine release syndrome (CRS) as an orally-delivered preventative therapy.
Cancer immunotherapies have been approved in rare and orphan blood cancers and so Poolbeg can see potential for POLB 001 in one or more of these cancer types.
"There is also a very active M&A market in this sector"POLB 001 in cancer immunotherapy-induced CRS will be developed alongside the company's existing portfolio of assets including its influenza program, its AI drug discovery work and oral delivery of GLP-1 for obesity and other metabolic diseases.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze